Local Radiotherapy for Urinary Bladder Cancer in Patients Not Eligible for Curative Treatment

Summary

The goal of this clinical trial is to improve the quality of life and prolong survival in bladder cancer patients unfit for curative treatment. The trial will compare the survival and symptoms of patients randomized to either local radiotherapy in addition to standard of care or standard of care alone. Using modern radiotherapy techniques, including hypofractionation and image-guided treatment adaptation, the aim is to deliver a well-tolerated, time-efficient, and effective treatment strategy for these patients. The trial collaborates with two ongoing exploratory biomarker studies collecting and analyzing potential biomarkers in urothelial bladder cancer. The hope is to provide biomarkers for prognosis and treatment response which is essential to ensure bladder cancer patients individualized treatment in the future, like those with breast and prostate cancer.

Eligibility

Inclusion Criteria:

1. Oral and written consent
2. Histologically confirmed MIBC with urothelial component
3. Male or female participants ≥ 18 years old
4. Deemed not to benefit from curative treatment at a multidisciplinary tumour conference (MDT) or having declined curative treatment of their own accord.

Exclusion Criteria:

1. Clinical Fragility Scale score ≥8
2. Previous pelvic RT with significant overlap
3. Visceral or bone metastases on CT scan
4. Multiple (\>3) lymph node metastases with a measurement of \>2 cm on CT scan
5. Planed for systemic treatment at the time of inclusion.
6. Local RT to the bladder indicated for the palliation of symptoms at the time of inclusion.

Conditions2

Browse More Trials